Cellzome extends J&J Alzheimer's collaboration
This article was originally published in Scrip
Executive Summary
The private drug discovery company Cellzome has extended its Alzheimer's disease collaboration with Ortho-McNeil-Janssen Pharmaceuticals and its affiliate Johnson & Johnson Pharmacetical Research & Developmentfor a further two years until March 2010. The collaboration has also been expanded to include an additional research programme in which Cellzome will map the Tau pathway which has been implicated in Alzheimer's and is a new avenue for drug discovery in the disease. The companies' two current research programmes target gamma secretase modulators and the amyloid precursor protein (APP) pathway - two more advanced areas of research for disease-modifying drugs against Alzheimer's. Under the latest agreement, Ortho-McNeil-Janssen has exclusive rights to the intellectual property on compounds chosen for development and commercialisation, and in exchange, Cellzome will receive a technology access fee and research support, as well as milestones and royalties on sales. No financial details were disclosed.
You may also be interested in...
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
Triumvira Takes A Different TAC With T-Cell Therapy For Solid Tumors
The private US/Canadian firm is taking a singular approach to T-cell therapy to tackle both solid and liquid tumors and hopes to have early data to back up its novel technology this year. An IPO could follow.